LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Romidepsin and tamoxifen cooperatively induce senescence of pancreatic cancer cells through downregulation of FOXM1 expression and induction of reactive oxygen species/lipid peroxidation

    Okuni, Noriko / Honma, Yoshio / Urano, Takeshi / Tamura, Kenji

    Molecular biology reports. 2022 May, v. 49, no. 5

    2022  

    Abstract: BACKGROUND: Although improvement has been made in therapeutic strategies against pancreatic carcinoma, overall survival has not significantly enhanced over the past decade. Thus, the establishment of better therapeutic regimens remains a high priority. ... ...

    Abstract BACKGROUND: Although improvement has been made in therapeutic strategies against pancreatic carcinoma, overall survival has not significantly enhanced over the past decade. Thus, the establishment of better therapeutic regimens remains a high priority. METHODS: Pancreatic cancer cell lines were incubated with romidepsin, an inhibitor of histone deacetylase, and tamoxifen, and their effects on cell growth, signaling and gene expression were analyzed. Xenografts of human pancreatic cancer CFPAC1 cells were medicated with romidepsin and tamoxifen to evaluate their effects on tumor growth. RESULTS: The inhibition of the growth of pancreatic cancer cells induced by romidepsin and tamoxifen was effectively reduced by N-acetyl cysteine and α-tocopherol, respectively. The combined treatment greatly induced reactive oxygen species production and mitochondrial lipid peroxidation, and these effects were prevented by N-acetyl cysteine and α-tocopherol. Tamoxifen enhanced romidepsin-induced cell senescence. FOXM1 expression was markedly downregulated in pancreatic cancer cells treated with romidepsin, and tamoxifen further reduced FOXM1 expression in cells treated with romidepsin. Siomycin A, an inhibitor of FOXM1, induced senescence in pancreatic cancer cells. Similar results were obtained in knockdown of FOXM1 expression by siRNA. CONCLUSION: Since FOXM1 is used as a prognostic marker and therapeutic target for pancreatic cancer, a combination of the clinically available drugs romidepsin and tamoxifen might be considered for the treatment of patients with pancreatic cancer.
    Keywords alpha-tocopherol ; carcinoma ; cell growth ; cell senescence ; cysteine ; gene expression ; histone deacetylase ; humans ; lipid peroxidation ; mitochondria ; molecular biology ; neoplasm cells ; pancreatic neoplasms ; reactive oxygen species ; tamoxifen ; xenotransplantation
    Language English
    Dates of publication 2022-05
    Size p. 3519-3529.
    Publishing place Springer Netherlands
    Document type Article
    ZDB-ID 186544-4
    ISSN 1573-4978 ; 0301-4851
    ISSN (online) 1573-4978
    ISSN 0301-4851
    DOI 10.1007/s11033-022-07192-9
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article ; Online: Romidepsin and tamoxifen cooperatively induce senescence of pancreatic cancer cells through downregulation of FOXM1 expression and induction of reactive oxygen species/lipid peroxidation.

    Okuni, Noriko / Honma, Yoshio / Urano, Takeshi / Tamura, Kenji

    Molecular biology reports

    2022  Volume 49, Issue 5, Page(s) 3519–3529

    Abstract: Background: Although improvement has been made in therapeutic strategies against pancreatic carcinoma, overall survival has not significantly enhanced over the past decade. Thus, the establishment of better therapeutic regimens remains a high priority.!# ...

    Abstract Background: Although improvement has been made in therapeutic strategies against pancreatic carcinoma, overall survival has not significantly enhanced over the past decade. Thus, the establishment of better therapeutic regimens remains a high priority.
    Methods: Pancreatic cancer cell lines were incubated with romidepsin, an inhibitor of histone deacetylase, and tamoxifen, and their effects on cell growth, signaling and gene expression were analyzed. Xenografts of human pancreatic cancer CFPAC1 cells were medicated with romidepsin and tamoxifen to evaluate their effects on tumor growth.
    Results: The inhibition of the growth of pancreatic cancer cells induced by romidepsin and tamoxifen was effectively reduced by N-acetyl cysteine and α-tocopherol, respectively. The combined treatment greatly induced reactive oxygen species production and mitochondrial lipid peroxidation, and these effects were prevented by N-acetyl cysteine and α-tocopherol. Tamoxifen enhanced romidepsin-induced cell senescence. FOXM1 expression was markedly downregulated in pancreatic cancer cells treated with romidepsin, and tamoxifen further reduced FOXM1 expression in cells treated with romidepsin. Siomycin A, an inhibitor of FOXM1, induced senescence in pancreatic cancer cells. Similar results were obtained in knockdown of FOXM1 expression by siRNA.
    Conclusion: Since FOXM1 is used as a prognostic marker and therapeutic target for pancreatic cancer, a combination of the clinically available drugs romidepsin and tamoxifen might be considered for the treatment of patients with pancreatic cancer.
    MeSH term(s) Animals ; Cell Line, Tumor ; Cell Proliferation ; Cysteine/metabolism ; Depsipeptides/pharmacology ; Down-Regulation ; Forkhead Box Protein M1/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Lipid Peroxidation ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/metabolism ; Reactive Oxygen Species/metabolism ; Tamoxifen/pharmacology ; alpha-Tocopherol/pharmacology ; Pancreatic Neoplasms
    Chemical Substances Depsipeptides ; FOXM1 protein, human ; Forkhead Box Protein M1 ; Reactive Oxygen Species ; Tamoxifen (094ZI81Y45) ; romidepsin (CX3T89XQBK) ; alpha-Tocopherol (H4N855PNZ1) ; Cysteine (K848JZ4886)
    Language English
    Publishing date 2022-01-31
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 186544-4
    ISSN 1573-4978 ; 0301-4851
    ISSN (online) 1573-4978
    ISSN 0301-4851
    DOI 10.1007/s11033-022-07192-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Gastrosplenic Fistula Due to Diffuse Large B-cell Lymphoma.

    Hojo, Nobumasa / Kitani, Kashu / Okuni, Noriko / Shikimi Matsuda, Hanako

    Internal medicine (Tokyo, Japan)

    2022  Volume 61, Issue 20, Page(s) 3149–3150

    MeSH term(s) Fistula ; Humans ; Lymphoma, Large B-Cell, Diffuse/complications ; Lymphoma, Large B-Cell, Diffuse/diagnostic imaging ; Lymphoma, Large B-Cell, Diffuse/pathology ; Splenic Diseases
    Language English
    Publishing date 2022-03-12
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 32371-8
    ISSN 1349-7235 ; 0021-5120 ; 0918-2918
    ISSN (online) 1349-7235
    ISSN 0021-5120 ; 0918-2918
    DOI 10.2169/internalmedicine.9150-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top